Current treatment practice in immunosuppression

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

New drugs have recently been added that may eventually replace the two-decade dominance of cyclosporin in solid organ transplantation. This cornerstone of immunosuppression was introduced by Borel [1] and Calne [2] in the mid-70s. In 1989, Starzl et al., after 2 years of preclinical experimentation, introduced tacrolimus (originally designated as FK506 by the Fujisawa Pharmaceutical Company of Japan) as a potent immunosuppressant for liver transplants [31. Also, in recent years, a variety of novel purine and pyrimidine biosynthesis inhibitors have been tested for transplantation therapy. The leading agent which appears to be replacing the 35-year position occupied by azathioprine is the semi-synthetic morpholinoethyl ester of mycophenolic acid (MPA), mycophenolate mofetil (MMF), introduced by Allison [4] and Sollinger [5], and developed by the Syntex Corporation (now Roche Pharmaceuticals). Others, affecting different intraor intercellular messages amplifying immunity, are in the pipeline.

Original languageEnglish
Pages (from-to)1307-1330
Number of pages24
JournalExpert Opinion on Pharmacotherapy
Volume1
Issue number7
StatePublished - Dec 1 2000

Fingerprint

Immunosuppression
Mycophenolic Acid
Tacrolimus
Pharmaceutical Preparations
Azathioprine
Organ Transplantation
Immunosuppressive Agents
Cyclosporine
Immunity
Japan
Therapeutics
Transplantation
Transplants
Liver
purine
pyrimidine

Keywords

  • Immimosuppression
  • Intestinal transplant
  • Kidney transplant
  • Liver transplant
  • Pancreas transplant
  • Rejection

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Current treatment practice in immunosuppression. / Ciancio, Gaetano; Burke, George W; Miller, Joshua.

In: Expert Opinion on Pharmacotherapy, Vol. 1, No. 7, 01.12.2000, p. 1307-1330.

Research output: Contribution to journalArticle

@article{62cf90bdbac24d5bac25c9bd8b0e7344,
title = "Current treatment practice in immunosuppression",
abstract = "New drugs have recently been added that may eventually replace the two-decade dominance of cyclosporin in solid organ transplantation. This cornerstone of immunosuppression was introduced by Borel [1] and Calne [2] in the mid-70s. In 1989, Starzl et al., after 2 years of preclinical experimentation, introduced tacrolimus (originally designated as FK506 by the Fujisawa Pharmaceutical Company of Japan) as a potent immunosuppressant for liver transplants [31. Also, in recent years, a variety of novel purine and pyrimidine biosynthesis inhibitors have been tested for transplantation therapy. The leading agent which appears to be replacing the 35-year position occupied by azathioprine is the semi-synthetic morpholinoethyl ester of mycophenolic acid (MPA), mycophenolate mofetil (MMF), introduced by Allison [4] and Sollinger [5], and developed by the Syntex Corporation (now Roche Pharmaceuticals). Others, affecting different intraor intercellular messages amplifying immunity, are in the pipeline.",
keywords = "Immimosuppression, Intestinal transplant, Kidney transplant, Liver transplant, Pancreas transplant, Rejection",
author = "Gaetano Ciancio and Burke, {George W} and Joshua Miller",
year = "2000",
month = "12",
day = "1",
language = "English",
volume = "1",
pages = "1307--1330",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Current treatment practice in immunosuppression

AU - Ciancio, Gaetano

AU - Burke, George W

AU - Miller, Joshua

PY - 2000/12/1

Y1 - 2000/12/1

N2 - New drugs have recently been added that may eventually replace the two-decade dominance of cyclosporin in solid organ transplantation. This cornerstone of immunosuppression was introduced by Borel [1] and Calne [2] in the mid-70s. In 1989, Starzl et al., after 2 years of preclinical experimentation, introduced tacrolimus (originally designated as FK506 by the Fujisawa Pharmaceutical Company of Japan) as a potent immunosuppressant for liver transplants [31. Also, in recent years, a variety of novel purine and pyrimidine biosynthesis inhibitors have been tested for transplantation therapy. The leading agent which appears to be replacing the 35-year position occupied by azathioprine is the semi-synthetic morpholinoethyl ester of mycophenolic acid (MPA), mycophenolate mofetil (MMF), introduced by Allison [4] and Sollinger [5], and developed by the Syntex Corporation (now Roche Pharmaceuticals). Others, affecting different intraor intercellular messages amplifying immunity, are in the pipeline.

AB - New drugs have recently been added that may eventually replace the two-decade dominance of cyclosporin in solid organ transplantation. This cornerstone of immunosuppression was introduced by Borel [1] and Calne [2] in the mid-70s. In 1989, Starzl et al., after 2 years of preclinical experimentation, introduced tacrolimus (originally designated as FK506 by the Fujisawa Pharmaceutical Company of Japan) as a potent immunosuppressant for liver transplants [31. Also, in recent years, a variety of novel purine and pyrimidine biosynthesis inhibitors have been tested for transplantation therapy. The leading agent which appears to be replacing the 35-year position occupied by azathioprine is the semi-synthetic morpholinoethyl ester of mycophenolic acid (MPA), mycophenolate mofetil (MMF), introduced by Allison [4] and Sollinger [5], and developed by the Syntex Corporation (now Roche Pharmaceuticals). Others, affecting different intraor intercellular messages amplifying immunity, are in the pipeline.

KW - Immimosuppression

KW - Intestinal transplant

KW - Kidney transplant

KW - Liver transplant

KW - Pancreas transplant

KW - Rejection

UR - http://www.scopus.com/inward/record.url?scp=0034572837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034572837&partnerID=8YFLogxK

M3 - Article

C2 - 11249467

AN - SCOPUS:0034572837

VL - 1

SP - 1307

EP - 1330

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 7

ER -